SEC ownership of REED'S, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001140215.

Comparable stake leader

Era Regenerative Medicine Ltd

Disclosed value leader

Era Regenerative Medicine Ltd

Comparable rows

21/33

Latest evidence

20 May 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
21 of 33
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Era Regenerative Medicine Ltd
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
20 May 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001140215
Issuer location
Norwalk, CT

Ownership snapshot

Top shareholders of REED'S, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Era Regenerative Medicine...
Disclosed value leader
Era Regenerative Medicine...
Comparable rows
21/33
Latest evidence
20 May 2026
13D/G 3/4/5 13F Lead comparable stake: 58% 12 rows are not safely comparable across share classes. 13D/G row: Era Regenerative Medicine Ltd Showing 1-8 of 33 holder rows.

Quick read

Era Regenerative Medicine Ltd leads the comparable SEC ownership view at 58%.

21 of 33 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Era Regenerative Medicine Ltd's linked filing trail.
Comparable ownership Top 5
Era Regenerative Medicine Ltd 58%
Shufen Deng 54%
WHITEBOX ADVISORS LLC 0.8%
Neal Cohane 0%
ARMISTICE CAPITAL, LLC 4.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 33 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Era Regenerative Medicine Ltd
13D/G 3/4/5
10%+ Owner
58%
$53,043,803
28,214,789 shares
+$2,021,506 04 Jun 2025
Shufen Deng
13D/G 3/4/5
DENG, SHUFEN · Director
54%
$15,907,672
6,363,069 shares
$0 20 May 2026
WHITEBOX ADVISORS LLC
13D/G
0.8%
$484,557
257,743 shares
$0 31 Dec 2024
Neal Cohane
3/4/5
Chief Operating Officer
0%
$675
675 shares
05 Jan 2026
ARMISTICE CAPITAL, LLC
13F
Company
13F
4.6%
$1,992,852
548,995 shares
31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
0.69%
$298,484
82,227 shares
31 Mar 2026
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
0.49%
$211,824
58,354 shares
31 Mar 2026
VANGUARD FIDUCIARY TRUST CO
13F
Company
13F
0.34%
$144,866
39,908 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 Aug 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 26 reporting-owner rows connected to REED'S, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
26
Largest Forms 3/4/5 holder
Union Square Park Capital Management, LLC
Net 12M change
$0
Latest report
27 Apr 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Union Square Park Capital Management, LLC 10%+ Owner $1,354,393 Filing P/S 14 Nov 2024
James C. Bass Director $1,003,500 Mixed 04 Feb 2022
Thomas W. Kosler Director $932,202 Mixed 01 Jul 2022
Lewis Jaffe Director $720,022 Mixed 04 Feb 2022
Thomas J. Spisak Cfo $686,052 Mixed 30 Sep 2021
Shufen Deng Director $599,999 Filing P/S 31 Dec 2024
Louis Imbrogno Jr. Director $576,883 Mixed 04 Feb 2022
John Bello Director $388,164 Mixed 10 Sep 2024
Norman E. Snyder Jr. CEO, Director $179,964 Mixed 29 Apr 2024
Rhonda Kallman Director $144,780 Mixed 04 Feb 2022
Joann Christine Tinnelly Cfo $68,539 Mixed 29 Apr 2024
Christopher Scott Burleson Cco $52,923 Mixed 29 Apr 2024
Neal Cohane Chief Operating Officer $675 Mixed 05 Jan 2026
Damian Francis Warshall Chief Operating Officer Mixed 27 Apr 2026
Douglas W. McCurdy Cfo Mixed 10 Feb 2025
Sam van Director Mixed 21 Oct 2024
Era Regenerative Medicine Ltd 10%+ Owner Mixed 04 Jun 2025
Yumin Dai Reed's (Asia) Exec Officer Mixed 22 Jan 2025
Rudolf Johannes Maria Bakker Director Mixed 14 Apr 2025
Leon M. Zaltzman Director, Other*, 10%+ Owner Mixed 10 Mar 2022

Recent insider transactions for REED'S, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Neal Cohane REED Common Stock 0 675 05 Jan 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .